BACKGROUND: The knowledge about and use of chemopreventive agents for prostate cancer by physicians has not been described. The Prostate Cancer Prevention Trial (PCPT) showed that finasteride was effective in reducing the incidence of prostate cancer. We examined the influence of the PCPT on finasteride prescribing within the Veterans Health Administration (VHA). METHODS: We assessed trends on monthly new and total prescriptions for finasteride filled within the VHA from January 2000 to December 2005. Additionally, all VHA urologists and a random sample of VHA primary care physicians (PCP) were surveyed about their use of finasteride. RESULTS: The number of men starting finasteride grew over the study period. Publication of the PCPT was not significantly associated with any change in this pattern (P = 0.45). Fifty-seven percent of urologists and 40% of PCPs endorsed prescribing finasteride more frequently in 2006 than 5 years prior. However, among those who reported changing prescribing patterns, fewer than 2% reported being influenced by the PCPT. Sixty-four percent of urologists and 80% of PCPs never prescribe finasteride for prostate cancer chemoprevention; 55% of urologists cited concerns of inducing high-grade tumors, whereas 52% of PCPs did not know it could be used for chemoprevention. CONCLUSIONS: The number of men starting finasteride in the VHA increased over time, but the change did not seem to be due to increased use of finasteride for chemoprevention. Publication of the PCPT seemed to have little influence over the study period. IMPACT: Physicians may not readily accept the use of chemopreventive agents for prostate cancer. (c) 2010 AACR.
BACKGROUND: The knowledge about and use of chemopreventive agents for prostate cancer by physicians has not been described. The Prostate Cancer Prevention Trial (PCPT) showed that finasteride was effective in reducing the incidence of prostate cancer. We examined the influence of the PCPT on finasteride prescribing within the Veterans Health Administration (VHA). METHODS: We assessed trends on monthly new and total prescriptions for finasteride filled within the VHA from January 2000 to December 2005. Additionally, all VHA urologists and a random sample of VHA primary care physicians (PCP) were surveyed about their use of finasteride. RESULTS: The number of men starting finasteride grew over the study period. Publication of the PCPT was not significantly associated with any change in this pattern (P = 0.45). Fifty-seven percent of urologists and 40% of PCPs endorsed prescribing finasteride more frequently in 2006 than 5 years prior. However, among those who reported changing prescribing patterns, fewer than 2% reported being influenced by the PCPT. Sixty-four percent of urologists and 80% of PCPs never prescribe finasteride for prostate cancer chemoprevention; 55% of urologists cited concerns of inducing high-grade tumors, whereas 52% of PCPs did not know it could be used for chemoprevention. CONCLUSIONS: The number of men starting finasteride in the VHA increased over time, but the change did not seem to be due to increased use of finasteride for chemoprevention. Publication of the PCPT seemed to have little influence over the study period. IMPACT: Physicians may not readily accept the use of chemopreventive agents for prostate cancer. (c) 2010 AACR.
Authors: Mike M Nguyen; Frederick R Ahmann; Raymond B Nagle; Chiu-Hsieh Hsu; Joseph A Tangrea; Howard L Parnes; Mitchell H Sokoloff; Matthew B Gretzer; H-H Sherry Chow Journal: Cancer Prev Res (Phila) Date: 2011-11-01
Authors: Nagi B Kumar; Julio Pow-Sang; Kathleen M Egan; Philippe E Spiess; Shohreh Dickinson; Raoul Salup; Mohamed Helal; Jerry McLarty; Christopher R Williams; Fred Schreiber; Howard L Parnes; Said Sebti; Aslam Kazi; Loveleen Kang; Gwen Quinn; Tiffany Smith; Binglin Yue; Karen Diaz; Ganna Chornokur; Theresa Crocker; Michael J Schell Journal: Cancer Prev Res (Phila) Date: 2015-04-14
Authors: Abdelrahman S Mayhoub; Laura Marler; Tamara P Kondratyuk; Eun-Jung Park; John M Pezzuto; Mark Cushman Journal: Bioorg Med Chem Date: 2012-10-23 Impact factor: 3.641
Authors: Mark A Preston; Lorelei A Mucci; Jane B Vaselkiv; Carl Ceraolo; Kathryn M Wilson; Claire H Pernar; Emily M Rencsok; Konrad H Stopsack; Sydney T Grob; Anna Plym; Edward L Giovannucci; Aria F Olumi; Adam S Kibel Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090
Authors: Stephen S Yoo; Timothy J Jorgensen; Ann R Kennedy; John D Boice; Alla Shapiro; Tom C-C Hu; Brian R Moyer; Marcy B Grace; Gary J Kelloff; Michael Fenech; Pataje G S Prasanna; C Norman Coleman Journal: J Radiol Prot Date: 2014-04-14 Impact factor: 1.394
Authors: Mark A Preston; Kathryn M Wilson; Sarah C Markt; Rongbin Ge; Christopher Morash; Meir J Stampfer; Massimo Loda; Edward Giovannucci; Lorelei A Mucci; Aria F Olumi Journal: JAMA Intern Med Date: 2014-08 Impact factor: 21.873
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Howard L Parnes; Lori M Minasian; Paul A Godley; M Scott Lucia; Leslie G Ford Journal: N Engl J Med Date: 2013-08-15 Impact factor: 91.245